// App-Quantinova.ai

SAT0157 : NINTEDANIB DOSE ADJUSTMENTS AND ADVERSE EVENTS IN PATIENTS WITH PROGRESSIVE AUTOIMMUNE DISEASE-RELATED INTERSTITIAL LUNG DISEASES IN THE INBUILD TRIAL

Researchers

Presenter

  • E. Volkmann

Principal Investigators

  • I. Castellv

  • S. Johnson

  • E. Matteson

  • J. Distler

  • J. Seibold

  • U. Costabel

  • A. James

  • C. Coeck

  • M. Quaresma

  • V. Cottin

Medical Centers

  • University of California, David Geffen School of Medicine, Department of Medicine, Division of Rheumatology, Los Angeles, CA, United States of America

  • GEICO and Hospital de la Santa Creu i Sant Pau, Department of Medical Oncology, Barcelona, Spain

  • Toronto Scleroderma Program, Department of Medicine, Toronto Western and Mount Sinai Hospitals, University of Toronto, Toronto, Canada, Toronto, Canada

  • Mayo Clinic College of Medicine and Science, Urology, Rochester, United States of America

  • University of Erlangen-Nuernberg, Erlangen, Germany

  • Scleroderma Research Consultants LLC, Aiken, South Carolina, United States of America

  • Ruhrlandklinik, University Hospital, University of Duisburg-Essen, Essen, Germany

  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany,

  • SCS Boehringer Ingelheim Comm. V., Brussels, Belgium

  • National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, Lyon, France,

Locations

  • United States

  • Spain

  • Canada

  • Germany

  • Belgium

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Idiopathic pulmonary fibrosis

Biomarkers

  • N/A

Drug/Treatment

  • Nintedanib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Formation Biologics Inc.

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved